European Medicines Agency committee recommends approval for Rett syndrome treatment.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for DAYBU® (trofinetide). This recommendation could lead to the first approved treatment for neurobehavioral symptoms of Rett syndrome in patients aged five and older within the EU. This development offers a new therapeutic option for individuals affected by this rare neurological disorder.